-+ 0.00%
-+ 0.00%
-+ 0.00%

Guggenheim Maintains Buy on ProMIS Neurosciences, Lowers Price Target to $35

Benzinga·02/06/2026 14:56:21
Listen to the news
Guggenheim analyst Eddie Hickman maintains ProMIS Neurosciences (NASDAQ:PMN) with a Buy and lowers the price target from $125 to $35.